The effect of an enhanced antenatal care package for the control of malaria and anaemia in pregnancy in Ghana

A cluster randomised controlled trial of an Enhanced AnteNatal Care service package for the control of Malaria and Anaemia in Pregnancy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN88917252

Enrollment

1663

Registered

2015-08-20

Start date

2012-09-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Malaria 2. Anaemia Pregnancy and Childbirth

Interventions

Control: Women in the control group will be provided with the current antenatal care package which includes: The taking of medical and obstetric history

measuring blood pressure, weight, height and temperature

measurement of symphysio-fundal height and foetal viability

routine urine and stool examinations, blood grouping, sickling test, VDRL for syphilis and HIV testing

screening for malaria and anaemia at the first antenatal visit and at for anaemia at 36 weeks gestation

giving intermittent preventive treatment for malaria and tetanus toxoid injections

folic acid and iron supplementation, presumptive de-worming, education on insecticide treated net use, dietary advice and scheduling of next antenatal care visits. Intervention: In addition to recei

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Pregnant woman visiting the antenatal clinic for the first time for the current pregnancy 2. Up to 32 weeks gestation at booking 3. Haermoglobin = 7g/dl at booking 4. Within the catchment area of the health facility

Exclusion criteria

Exclusion criteria: 1. Pregnant woman with a history or presence of any systemic illness likely to interfere with interpretation of trial results e.g. HIV-AIDS, sickle cell disease, G-6PD deficiency 2. Pregnant woman with any significant illness at time of screening that required hospitalization (including severe anaemia)

Design outcomes

Primary

Measure	Time frame
1. Prevalence of malaria parasitaemia at 4-8 weeks after enrollment 2. Prevalence of anaemia 4-8 weeks after enrollment	—

Secondary

Measure	Time frame
1. Prevalence of malaria parasitaemia prior to delivery 2. Prevalence of anaemia prior to delivery 3. Prevalence of low birth weight 4. Prevalence of sub-optimal pregnancy outcomes (still births, abortions, miscarriages) 5. Level of pregnant women's knowledge about malaria and anaemia in pregnancy 6. Level of pregnant women's adherence to health advice 7. Feasibility and acceptability of the use of HCS and RDT during antenatal care	—

Measure

Time frame

1. Prevalence of malaria parasitaemia prior to delivery 2. Prevalence of anaemia prior to delivery 3. Prevalence of low birth weight 4. Prevalence of sub-optimal pregnancy outcomes (still births, abortions, miscarriages) 5. Level of pregnant women's knowledge about malaria and anaemia in pregnancy 6. Level of pregnant women's adherence to health advice 7. Feasibility and acceptability of the use of HCS and RDT during antenatal care

—

Countries

Ghana

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026